Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.60 |
| ▸ | HTR1A | P08908 | 2/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.51 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.49 |
| ▸ | HTR6 | P50406 | 3/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.45 |
| ▸ | HTR2C | P28335 | 2/20 | 0.45 |
| ▸ | HTR2B | P41595 | 2/20 | 0.45 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27512588 | 0.99 | ACHE (0.58) | ACHEHTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5585315 | 0.87 | ADRB1 (0.49) | ACHEHTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1275993 | 0.84 | ACHE (0.60) | ACHEHTR1ASLC6A2SLC6A3ALKBH1 | |
| SCHEMBL905866 | 0.80 | HTR6 (0.51) | ACHEHTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5258581 | 0.80 | ADRB1 (0.52) | ACHETAAR1ADRB1ALDH1A1KDM4E | |
| SCHEMBL3104344 | 0.80 | HTR2C (0.57) | HTR1ASLC6A2SLC6A4SLC6A3TAAR1 | |
| Hydrochloric Acid SCHEMBL31061265 | 0.78 | HTR2C (0.58) | HTR1ASLC6A2SLC6A4SLC6A3TAAR1 | |
| SCHEMBL30423191 | 0.78 | ADRB1 (0.50) | ACHEADRB1ALDH1A1KDM4ECYP1A2 | |
| SCHEMBL2792154 | 0.77 | ADRB1 (0.55) | ACHEADRB1ALDH1A1KDM4EHTR2C | |
| SCHEMBL20443370 | 0.77 | ADRB1 (0.52) | ACHEADRB1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100451016-C | Piperazinylpyrazine compounds as agonists or antagonists of serotonin 5ht-2 receptors | BIOVITRUM AB (SE) | 2009-01-14 | — | — | CN | claimed |
| US-7247633-B2 | Pyrimidine compounds and their use | BIOVITRUM AB (SE) | 2007-07-24 | — | — | US | claimed |
| CN-1876648-A | Piperazinylpyrazine compounds as agonists or antagonists of serotonin 5ht-2 receptors | BIOVITRUM AB (SE) | 2006-12-13 | — | — | CN | claimed |
| US-20050054656-A1 | 5-HT receptor ligands and uses thereof | PFIZER INC | 2005-03-10 | — | — | US | claimed |
| EP-1401819-A1 | 5-HT RECEPTOR LIGANDS AND USES THEREOF | Pfizer Products Inc. (US) | 2004-03-31 | — | — | EP | claimed |
| CN-1479727-A | Piperazinylpyrazine compounds as agonists or antagonists of the 5-hydroxytryptamine 5 HT-2 receptor | �Ȱ�ά����ķ�ɷݹ�˾ | 2004-03-03 | — | — | CN | claimed |
| US-20040014767-A1 | Novel compounds and their use | BIOVITRUM AB, A SWEDISH CORPORATION | 2004-01-22 | — | — | US | claimed |
| EP-1335907-A1 | PIPERAZINYLPYRAZINE COMPOUNDS AS AGONIST OR ANTAGONIST OF SEROTONIN 5HT-2 RECEPTOR | BIOVITRUM AB (SE) | 2003-08-20 | — | — | EP | claimed |
| US-20030105106-A1 | 5-HT receptor ligands and uses thereof | CHIANG PHOEBE (US) | 2003-06-05 | — | — | US | claimed |
| WO-2003000663-A1 | 5-HT RECEPTOR LIGANDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | claimed |
| US-20020147200-A1 | Novel compounds and their use | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2002-10-10 | — | — | US | claimed |
| WO-2002040456-A1 | PIPERAZINYLPYRAZINE COMPOUNDS AS AGONIST OR ANTAGONIST OF SEROTONIN 5HT-2 RECEPTOR | BIOVITRUM AB (SE) | 2002-05-23 | — | — | WO | claimed |
| US-20110152272-A1 | Treatment Of Incontinence | PFIZER INC | 2011-06-23 | — | — | US | disclosed |
| EP-2277513-A2 | Treatment of incontinence with 5htc2 agonists | Pfizer Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| CN-1780612-B | Treatment of incontinence with 5HT2C agonists. | PFIZER | 2010-12-01 | — | — | CN | disclosed |
| CN-100451016-C | Piperazinylpyrazine compounds as agonists or antagonists of serotonin 5ht-2 receptors | BIOVITRUM AB (SE) | 2009-01-14 | — | — | CN | disclosed |
| US-20030105106-A1 | 5-HT receptor ligands and uses thereof | CHIANG PHOEBE (US) | 2003-06-05 | — | — | US | disclosed |
| WO-2003000663-A1 | 5-HT RECEPTOR LIGANDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| US-20020147200-A1 | Novel compounds and their use | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2002-10-10 | — | — | US | disclosed |
| WO-2002040456-A1 | PIPERAZINYLPYRAZINE COMPOUNDS AS AGONIST OR ANTAGONIST OF SEROTONIN 5HT-2 RECEPTOR | BIOVITRUM AB (SE) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105106-A1 | 5-HT receptor ligands and uses thereof | HTR1A, HTR2A, HTR5A | ACHE 638/4885HTR1A 1/4885SLC6A2 74/4885 |
| US-20110152272-A1 | Treatment Of Incontinence | HTR2C, HTR5A, ADRA2C | ACHE 529/4885HTR1A 15/4885SLC6A2 36/4885 |
| US-20050054656-A1 | 5-HT receptor ligands and uses thereof | HTR2A, HTR1A, HTR5A | ACHE 610/4885HTR1A 2/4885SLC6A2 67/4885 |
| US-20020147200-A1 | Novel compounds and their use | BRIX1, UGT1A1, NR5A1 | ACHE 1499/4885HTR1A 611/4885SLC6A2 2442/4885 |
| US-20040014767-A1 | Novel compounds and their use | BRIX1, UGT1A1, NR5A1 | ACHE 1499/4885HTR1A 611/4885SLC6A2 2442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.